Andrew Marshall is a partner at Haystack Science. He worked at Scion Life Sciences, an early-stage venture fund, and for over two decades led Nature Biotechnology. He has written hundreds of articles and editorials about biotech in the trade and popular media, including The Economist and Popular Science. He is an EIR at Memorial Sloan Kettering Cancer Center and on the Advisory Committee of Robertson Translational Fund, the NYU Therapeutics Alliance, a
Board member of Eureka Institute for Translational Science and a Voluntary Professor at the University of Miami. Scientific American cited him as one of the 100 most influential people in biotechnology. He obtained a BSc with Honors and his PhD and postdoctoral experience in molecular biology and microbiology at King’s College London, where he was awarded the Helen White Prize.